Home
MIRM
MIRM News

Latest Mirum Pharmaceuticals Inc. (MIRM) News on April 19, 2025

MT Newswires

5 days ago

Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Business Wire

5 days ago

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 days ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Zacks

16 days ago

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Zacks

22 days ago

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

MT Newswires

23 days ago

Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus

LIVMARLI Now Approved in Japan for ALGS and PFIC

Business Wire

23 days ago

LIVMARLI Now Approved in Japan for ALGS and PFIC

Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks in the US Market

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a month ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a month ago

Mirum Pharmaceuticals Insider Sold Shares Worth $676,928, According to a Recent SEC Filing

Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Simply Wall St.

2 months ago

Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

2 months ago

Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Mirum Pharmaceuticals Inc Earnings Call

MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

Zacks

2 months ago

MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

GuruFocus.com

2 months ago

Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ...

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Zacks

2 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Business Wire

2 months ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts

Insider Monkey

2 months ago

Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know

Zacks

2 months ago

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know

MT Newswires

2 months ago

Mirum Pharmaceuticals Says US FDA Approves Cerebrotendinous Xanthomatosis' Treatment Drug

Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Business Wire

2 months ago

Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Mirum drug for rare genetic disease gains FDA approval

BioPharma Dive

2 months ago

Mirum drug for rare genetic disease gains FDA approval

MT Newswires

2 months ago

Mirum Pharmaceuticals' Lipid Storage Disease Treatment Gets FDA Approval

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Business Wire

2 months ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

High Growth Tech Stocks in United States to Watch

Simply Wall St.

2 months ago

High Growth Tech Stocks in United States to Watch

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Mirum Pharmaceuticals Insider Sold Shares Worth $327,658, According to a Recent SEC Filing

Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

3 months ago

Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?

MT Newswires

3 months ago

Mirum Pharmaceuticals Insider Sold Shares Worth $319,598, According to a Recent SEC Filing

MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Zacks

3 months ago

MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks in the United States

Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?

Zacks

3 months ago

Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?

Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

3 months ago

Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Business Wire

3 months ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Mirum Pharmaceuticals Insider Sold Shares Worth $320,644, According to a Recent SEC Filing

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

3 months ago

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Path To Profitability

Simply Wall St.

4 months ago

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Path To Profitability

Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?

Zacks

4 months ago

Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities

TipRanks

4 months ago

Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities

Mirum Shares Surge More Than 90% in 6 Months: Here's Why

Zacks

5 months ago

Mirum Shares Surge More Than 90% in 6 Months: Here's Why

Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Simply Wall St.

5 months ago

Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting

Business Wire

5 months ago

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting

Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

GuruFocus.com

5 months ago

Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ...

Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised

Zacks

5 months ago

Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

Zacks

5 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

MT Newswires

5 months ago

Mirum Pharmaceuticals' Q3 Loss Narrows, Revenue Rises

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire

5 months ago

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Business Wire

5 months ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

5 months ago

High Growth Tech Stocks In The United States To Watch

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Business Wire

5 months ago

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know

Zacks

6 months ago

Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Business Wire

6 months ago

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth

Insider Monkey

6 months ago

Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

6 months ago

Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

Business Wire

6 months ago

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

GuruFocus.com

6 months ago

Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ...

Exploring High Growth Tech Stocks In The US October 2024

Simply Wall St.

7 months ago

Exploring High Growth Tech Stocks In The US October 2024

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Investor's Business Daily

7 months ago

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?

Zacks

7 months ago

Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?

High Growth Tech Stocks To Watch In August 2024

Simply Wall St.

8 months ago

High Growth Tech Stocks To Watch In August 2024

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Business Wire

8 months ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

MT Newswires

8 months ago

Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern

Zacks

8 months ago

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Simply Wall St.

8 months ago

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

8 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top

Zacks

8 months ago

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

Zacks

8 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Business Wire

8 months ago

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Business Wire

9 months ago

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?

Zacks

9 months ago

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?

MT Newswires

9 months ago

Mirum Pharmaceuticals Gets FDA Label Expansion Approval for Liver Disease Treatment; Shares Jump

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Business Wire

9 months ago

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Mirum Pharmaceuticals (NASDAQ:MIRM) delivers shareholders solid 23% CAGR over 5 years, surging 11% in the last week alone

Simply Wall St.

9 months ago

Mirum Pharmaceuticals (NASDAQ:MIRM) delivers shareholders solid 23% CAGR over 5 years, surging 11% in the last week alone

Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves

Investor's Business Daily

9 months ago

Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion

Zacks

9 months ago

Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion

Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why

Zacks

9 months ago

Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why

MT Newswires

9 months ago

Mirum Pharmaceuticals Gets Marketing Approval for Livmarli in Europe

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

Business Wire

9 months ago

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50

Investor's Business Daily

10 months ago

MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50

MT Newswires

10 months ago

Mirum Pharmaceuticals Submits New Drug Application for Cholesterol Metabolism Treatment

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Business Wire

10 months ago

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling

Investor's Business Daily

10 months ago

Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling

MT Newswires

10 months ago

Stifel Adjusts Mirum Pharmaceuticals Price Target to $66 From $48, Maintains Buy Rating

Mirum (MIRM) Soars on Interim Data From Liver Disease Studies

Zacks

10 months ago

Mirum (MIRM) Soars on Interim Data From Liver Disease Studies

MT Newswires

10 months ago

Evercore ISI Adjusts Price Target on Mirum Pharmaceuticals to $62 From $53, Maintains Outperform Rating

MT Newswires

10 months ago

Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $71 From $60, Maintains Strong Buy Rating

MT Newswires

10 months ago

Citigroup Adjusts Price Target on Mirum Pharmaceuticals to $64 From $38, Maintains Buy Rating

MT Newswires

10 months ago

JMP Securities Adjusts Price Target on Mirum Pharmaceuticals to $68 From $66, Maintains Market Outperform Rating

MT Newswires

10 months ago

Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $57 From $53, Maintains Overweight Rating

MT Newswires

10 months ago

JPMorgan Adjusts Price Target on Mirum Pharmaceuticals to $39 From $31, Maintains Overweight Rating

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

Zacks

10 months ago

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

MT Newswires

10 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

10 months ago

Sector Update: Health Care Stocks Ease in Afternoon Trading

Share on Social Networks: